Setback for Novartis in Corona drug study

Melania
A clinical study by the pharmaceutical company for the drug canakinumab in hospitalized coronavirus patients failed to achieve both of its main goals. The drug did not increase the chances of survival of patients with pneumonia caused by Covid-19 and cytokine release syndrome, the Swiss company announced. The drug, which is known under the brand name Ilaris, remains an option in the approved fields for the treatment of autoinflammatory diseases. Novartis also said the results would not affect other ongoing studies of canakinumab, including its possible use against a form of lung cancer.
(Visited 1 times, 1 visits today)

Tags: suchen suche search tag anzeigen besucherzahl browser design domain inhalt jahr karpfen konto problem inhalt schalten modellbahn spielemax spiel tag webseite preise werbung

Reichsmarschall Göring hatte eine Märklin Modelleisenbahn >>> read more



Schreibe einen Kommentar


ID for Download Paper 34951